Replies to post #165939 on Biotech Values

[DewDiligence]

Coherus/BAX announce positive PK study for Enbrel FoB, CHS-0214:

http://finance.yahoo.com/news/coherus-announces-chs-0214-proposed-115900393.html

CHS-0214 is being developed for the EU, Canada, Brazil, and other emerging markets.

(In the US, AMGN’s patent protection precludes an FoB until 2028, until the patent is successfully challenged: #msg-69263618.)

[DewDiligence]

CHRS, BAX modify FoB collaboration for Enbrel to include an equity purchase by BAX of an unspecified size and certain other changes:

http://finance.yahoo.com/news/coherus-biosciences-baxter-announce-amendment-120000334.html